Literature DB >> 9355001

The Stanmore total hip arthroplasty. A 15- to 20-year follow-up study.

D Emery1, A Britton, H Clarke, M Grover.   

Abstract

An ongoing study was made of 804 primary Stanmore total hip prostheses implanted in 839 patients between 1973 and 1991. The earliest surviving implants were brought back for radiologic and clinical review in 1995 at an average of 17 years after surgery. The remainder of the patients still living were sent a questionnaire to assess their current status. Survivorship was 95% at 10 years, 85% at 15 years, and 73% at 20 years. The average Merle d'Aubigné-Postel score was excellent up until 14 years. Patient satisfaction remained high until 22 years. Overall, 10% of the prostheses had failed. The results of this study suggest that the Stanmore prosthesis is capable of producing satisfactory long-term results that compare favorably with those of other cemented prostheses.

Entities:  

Mesh:

Year:  1997        PMID: 9355001     DOI: 10.1016/s0883-5403(97)90001-2

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  4 in total

1.  Incidence of contralateral THA after index THA for osteoarthritis.

Authors:  Siraj A Sayeed; Aaron J Johnson; David E Jaffe; Michael A Mont
Journal:  Clin Orthop Relat Res       Date:  2012-02       Impact factor: 4.176

2.  Primary Stanmore total hip arthroplasty with increased cup loosening in rheumatoid patients.

Authors:  J C T van der Lugt; R Onstenk; R G H H Nelissen
Journal:  Int Orthop       Date:  2003-10-08       Impact factor: 3.075

3.  Palacos compared to Palamed bone cement in total hip replacement: a randomized controlled trial.

Authors:  Joris E Meinardi; Edward R Valstar; Paul Van Der Voort; Bart L Kaptein; Marta Fiocco; Rob G H H Nelissen
Journal:  Acta Orthop       Date:  2016-06-22       Impact factor: 3.717

4.  Contralateral total hip arthroplasty after hindquarter amputation.

Authors:  Scott M M Sommerville; James T Patton; Jonathan C Luscombe; Robert J Grimer
Journal:  Sarcoma       Date:  2006-10-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.